Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;56(2):197-9.
doi: 10.4103/0019-5545.130510.

Extrapyramidal side effects with low doses of amisulpride

Nikhiles Mandal  1 , Om P Singh  1 , Subrata Sen  1
Affiliations

Extrapyramidal side effects with low doses of amisulpride

Nikhiles Mandal et al. Indian J Psychiatry. 2014 Apr.

Abstract

Amisulpride, the newly introduced antipsychotic in India, is claimed to be effective in both positive and negative symptom schizophrenia and related disorders, though it has little or no action on serotonergic receptors. Limbic selectivity and lower striatal dopaminergic receptor binding capacity causes very low incidence of EPS. But, in clinical practice, we are getting EPS with this drug even at lower doses. We have reported three cases of akathisia, acute dystonia, and drug-induced Parkinsonism with low doses of amisulpride. So, we should keep this side effect in mind when using amisulpride. In fact, more studies are required in our country to find out the incidence of EPS and other associated mechanism.

Keywords: Amisulpride; EPS; limbic selectivity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

References

    1. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999;39:25–32. - PubMed
    1. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect?. An In vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients. Am J Psychiatry. 2003;160:1413–20. - PubMed
    1. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D 2 /D 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280:73–82. - PubMed
    1. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999;156:610–6. - PubMed
    1. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “Atypical” antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180–90. - PubMed